Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000562898 | SCV000666114 | likely benign | Hereditary cancer-predisposing syndrome | 2016-11-29 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Labcorp Genetics |
RCV002060431 | SCV002397648 | likely benign | Hereditary breast ovarian cancer syndrome | 2022-08-04 | criteria provided, single submitter | clinical testing | |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV003478232 | SCV004220673 | uncertain significance | not provided | 2023-05-11 | criteria provided, single submitter | clinical testing | To the best of our knowledge, the variant has not been reported in individuals with BRCA2-related conditions in the published literature. It also has not been reported in large, multi-ethnic general populations (http://gnomad.broadinstitute.org). Analysis of this variant using software algorithms for the prediction of the effect of nucleotide changes on splicing yielded predictions that this variant does not affect BRCA2 mRNA splicing . Based on the available information, we are unable to determine the clinical significance of this variant. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV005240216 | SCV005883063 | likely benign | not specified | 2024-12-06 | criteria provided, single submitter | clinical testing |